Loading
A phase 3 trial of Epcoritamab, Rituximab, Lenalidomide in follicular lymphoma, run by Genmab, active and no longer recruiting.
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma is a phase 3 interventional study registered as NCT05409066 by Genmab, with 549 participants enrolled, started 2022-09-20 and due to reach its primary completion in 2029-12. Interventions recorded: Epcoritamab, Rituximab, Lenalidomide. Conditions listed: Follicular Lymphoma (FL). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Epcoritamab, Genmab, Lenalidomide, PROTACs & molecular glues (targeted protein degradation).
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Rituximab, Follicular lymphoma.
Shares Epcoritamab, Genmab, Lenalidomide, PROTACs & molecular glues (targeted protein degradation).
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Rituximab, T-cell engagers (bispecific).
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Rituximab, T-cell engagers (bispecific).
Shares Epcoritamab, Genmab, T-cell engagers (bispecific), Follicular lymphoma.
Shares Epcoritamab, Genmab, Lenalidomide, Rituximab.
Shares Epcoritamab, Genmab, Rituximab, T-cell engagers (bispecific).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/